Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lindsay E King

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Immunological Methods|March 15, 2012
Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeuticMark Dysinger, Lindsay E King
Bioanalysis|July 31, 2015
Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assaysSeema Kumar, Lindsay E King, Tracey H Clark, et al.
Scientific Reports|July 24, 2024
SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)Pitchumani Sivakumar, Michelle Saul, Douglas Robinson, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|March 26, 2023
Mass cytometry for the multiplexed quantification and characterization of target expression on circulating cells in whole bloodChad R Stevens, Kondala Atkuri, Daniele L Menard, et al.
The AAPS Journal|April 2, 2013
Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulationMarian Kelley, Ago B Ahene, Boris Gorovits, et al.
The AAPS Journal|April 2, 2014
Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization TeamLindsay E King, Esme Farley, Mami Imazato, et al.
The AAPS Journal|March 1, 2014
A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugateDhaval K Shah, Lindsay E King, Xiaogang Han, et al.
The AAPS Journal|April 1, 2016
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)Aman P Singh, Katie F Maass, Alison M Betts, et al.
The AAPS Journal|May 21, 2016
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab OzogamicinAlison M Betts, Nahor Haddish-Berhane, John Tolsma, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 30, 2019
A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro DataHannah M Jones, Zhiwei Zhang, Paul Jasper, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Immunological Methods|March 15, 2012
Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeuticMark Dysinger, Lindsay E King
Bioanalysis|July 31, 2015
Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assaysSeema Kumar, Lindsay E King, Tracey H Clark, et al.
Scientific Reports|July 24, 2024
SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)Pitchumani Sivakumar, Michelle Saul, Douglas Robinson, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|March 26, 2023
Mass cytometry for the multiplexed quantification and characterization of target expression on circulating cells in whole bloodChad R Stevens, Kondala Atkuri, Daniele L Menard, et al.
The AAPS Journal|April 2, 2013
Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulationMarian Kelley, Ago B Ahene, Boris Gorovits, et al.
The AAPS Journal|April 2, 2014
Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization TeamLindsay E King, Esme Farley, Mami Imazato, et al.
The AAPS Journal|March 1, 2014
A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugateDhaval K Shah, Lindsay E King, Xiaogang Han, et al.
The AAPS Journal|April 1, 2016
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)Aman P Singh, Katie F Maass, Alison M Betts, et al.
The AAPS Journal|May 21, 2016
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab OzogamicinAlison M Betts, Nahor Haddish-Berhane, John Tolsma, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 30, 2019
A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro DataHannah M Jones, Zhiwei Zhang, Paul Jasper, et al.
Pageof 2